EUVIMEDEUVIMED entdecken
Crossref

PAD4 inhibitor GSK484 alleviates doxorubicin-induced myocardial fibrosis by modulating profibrotic, inflammatory and apoptotic signaling pathways in mice

Doa'a G F Al-U'datt, Ayssar Tashtush, Muhammad Al-U'datt, Carole C Tranchant, Sara Al-Masaed, Saied Jaradat

European Journal of Pharmacology · 2026

DOI: 10.1016/j.ejphar.2026.179239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2026. Verfasst von Doa'a G F Al-U'datt und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Biochemistry, Faculty of Medicine, Jordan University of Science and Technology, Irbid, 22110, Jordan. Electronic address…. Hauptthemen laut MEDLINE: Doxorubicin, Apoptosis, Myocardium, Cardiomyopathies. Die Arbeit nennt 90 Literaturangaben. Gefördert von: Jordan University of Science and Technology, Université de Moncton.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The therapeutic potential of selective PAD4 inhibitors such as GSK484 in mitigating adverse cardiac remodeling remains to be established. This study tested the hypothesis that PAD4 inhibition by GSK484 alleviates doxorubicin (DOX)-induced myocardial fibrosis in mice by modulating the expression of fibrosis-related biomarkers. METHODS: Male BALB/c mice were injected intraperitoneally with DOX (6 mg/kg/day) or saline (control) for three days, followed by intraperitoneal injection of GSK484 (0.5 mg/kg/day) for seven days. Blood analytes were determined. Left ventricular tissues were analyzed for PAD4 protein expression, fibrotic content by Masson's staining, as well as mRNA expression of inflammatory, fibrotic, proliferation and apoptosis biomarkers by quantitative PCR. RESULTS: Significant elevation of fibrotic content and PAD4 protein expression was evidenced in the heart of DOX-induced cardiomyopathic mice relative to controls, together with significantly lower serum high-density lipoprotein. These alterations were prevented in DOX-induced cardiomyopathic mice treated with GSK484. Likewise, GSK484 alleviated the upregulation of biomarkers of inflammation (IL-6), fibrosis (fibronectin, MMP-2, MMP-9, SMAD1, SMAD6, SMAD7, BMP-2) and apoptosis (caspase 9, BAX, BCL-2) in this model. Moreover, GSK484 modified the significance and direction of the correlations between PAD4 transcription levels and several other biomarkers. CONCLUSION: Findings show that PAD4 inhibition by GSK484 is associated with reduced fibrosis in DOX-induced cardiomyopathy, accompanied by changes in key inflammatory and profibrotic signaling markers. While the underlying mechanisms remain unclear, findings support further investigation of PAD4 inhibition as a potential therapeutic strategy for fibrotic cardiac diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinApoptosisMyocardiumCardiomyopathiesEnzyme InhibitorsAnimalsMaleFibrosisSignal TransductionMiceMice, Inbred BALB CInflammationImidazoles

Stichwörter der Autor:innen

Cardiac injuryFibrosisGSK484InflammationNETosisPAD4 inhibition

Substanzen

DoxorubicinEnzyme InhibitorsGSK484Imidazoles

Autor:innen und Institutionen

  • Department of Physiology and Biochemistry, Faculty of Medicine, Jordan University of Science and Technology, Irbid, 22110, Jordan. Electronic address: dgaludatt@just.edu.jo.
  • Department of Physiology and Biochemistry, Faculty of Medicine, Jordan University of Science and Technology, Irbid, 22110, Jordan.
  • Department of Nutrition and Food Technology, Faculty of Agriculture, Jordan University of Science and Technology, P.O. Box 3030, Irbid, 22110, Jordan.
  • Faculty of Health Sciences and Community Services, School of Food Science, Nutrition and Family Studies, Université de Moncton, New Brunswick, Canada.
  • Princess Haya Biotechnology Center, Jordan University of Science and Technology, Irbid, 22110, Jordan.

Förderung

  • Jordan University of Science and Technology
  • Université de Moncton

Zitieren

APA

Al-U'datt, D. G. F., Tashtush, A., Al-U'datt, M., Tranchant, C. C., Al-Masaed, S., & Jaradat, S. (2026). PAD4 inhibitor GSK484 alleviates doxorubicin-induced myocardial fibrosis by modulating profibrotic, inflammatory and apoptotic signaling pathways in mice. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2026.179239

Vancouver

Al-U'datt DGF, Tashtush A, Al-U'datt M, Tranchant CC, Al-Masaed S, Jaradat S. PAD4 inhibitor GSK484 alleviates doxorubicin-induced myocardial fibrosis by modulating profibrotic, inflammatory and apoptotic signaling pathways in mice. European Journal of Pharmacology. 2026. doi:10.1016/j.ejphar.2026.179239

BibTeX
@article{AlUdatt2026,
  author = {Al-U'datt, Doa'a G F and Tashtush, Ayssar and Al-U'datt, Muhammad and Tranchant, Carole C and Al-Masaed, Sara and Jaradat, Saied},
  title = {PAD4 inhibitor GSK484 alleviates doxorubicin-induced myocardial fibrosis by modulating profibrotic, inflammatory and apoptotic signaling pathways in mice},
  journal = {European Journal of Pharmacology},
  year = {2026},
  doi = {10.1016/j.ejphar.2026.179239}
}
Kostenlos starten →